MAKO Surgical Corp. (Nasdaq:MAKO), a medical device company that
markets its RIO® Robotic Arm Interactive Orthopedic surgical
platform, MAKOplasty® joint specific applications and proprietary
RESTORIS® implants that together enable orthopedic surgeons to
consistently, reproducibly and precisely treat patient specific
osteoarthritic disease, today announced that Scott D. Flora and
Jonathan T. "Jack" Lord, M.D. have joined the Company's Board of
Directors.
"Scott and Jack are exciting additions to the MAKO Board," said
Charles W. Federico, Chairman of the Board of Directors. "Both
bring substantial strategic value to the board based on their
experience and prior successes, and we look forward to their
contributions at MAKO."
Mr. Flora is currently the President, Chief Executive Office and
a director of OmniGuide Inc., a medical device company. He served
as the Global Business Unit President for the surgical device
division of Covidien plc, a global healthcare products company,
from November 2006 until June 2011. From 1994 through 2006, Mr.
Flora served in numerous positions at Smith & Nephew plc, a
global medical technology company, including President and General
Manager of the orthopedics reconstruction division, General Manager
of the trauma and clinical therapies divisions, Senior Vice
President of United States and Europe, Senior Vice President of
Smith & Nephew Healthcare, and Senior Vice President of the
orthopedics division. From September 2011 until January 2013, Mr.
Flora served on the board of directors of Tengion, a regenerative
medicine company focused on discovering, developing, manufacturing
and commercializing a range of neo organs. Mr. Flora received a
bachelor of science degree in marketing from Millikin University
and has participated in professional development programs at Yale
University, the Wharton School of the University of Pennsylvania,
the Kellogg School of Management, INSEAD, and Pennsylvania State
University.
Dr. Lord is currently the Chairman of the Board of Directors of
Dexcom, Inc., a medical device company. He recently completed an
assignment as Chief Operating Officer of the Miller School of
Medicine and UHealth-University of Miami Health System, and is
currently a Professor of Clinical Pathology. Dr. Lord served as the
Chief Innovation Officer of the University of Miami from September
2011 to March 2012 and as the Chief Executive Officer of
Navigenics, a personal genomics company, from May 2009 to December
2009. Prior to that, he was the Chief Innovation Officer and Senior
Vice President of Humana, an insurance products and health and
wellness services company, from 2000 to 2009. Dr. Lord is a
board-certified forensic pathologist who began his medical career
in the U.S. Navy and later served as chief operating officer of the
American Hospital Association and several biotech companies. Dr.
Lord also serves or has served as a member of a number of boards
and organizations, including the Centers for Disease Control and
Prevention's Advisory Committee to the Director, the National
Advisory Council for Healthcare Research and Quality, which advises
the U.S. Secretary of Health and Human Services, and the Joint
Commission on Accreditation of Health Care Organizations. In
addition to currently serving as the Chairman of Dexcom, Inc., Dr.
Lord also serves as a Director at Stericycle, Inc. and Vigilant
Biosciences, Inc., and serves on advisory board roles for Serco PLC
(UK), Anthelio Health and Third Rock Ventures, LLC. He has
earned certificates in Governance and Audit from the Harvard
Business School. Dr. Lord received an M.D. from the University
of Miami School of Medicine and a bachelor of science degree in
chemistry from the University of Miami.
"Jack and Scott provide MAKO with impressive clinical and
industry expertise," said Maurice R. Ferré, M.D., MAKO's President
and Chief Executive Officer. "I look forward to working with them
towards MAKO's continuing growth and success."
About MAKO Surgical Corp.
MAKO Surgical Corp. is a medical device company that markets its
RIO® Robotic-Arm Interactive Orthopedic system, joint specific
applications for the knee and hip, and proprietary RESTORIS®
implants for orthopedic procedures called MAKOplasty®. The RIO is a
surgeon-interactive tactile surgical platform that incorporates a
robotic arm and patient-specific visualization technology, which
enables precise, consistently reproducible bone resection for the
accurate insertion and alignment of MAKO's RESTORIS implants. The
MAKOplasty solution incorporates technologies enabled by an
intellectual property portfolio including more than 300 U.S. and
foreign, owned and licensed, patents and patent applications.
Additional information can be found at www.makosurgical.com.
Forward-Looking Statements
This press release contains forward-looking statements
regarding, among other things, statements related to expectations,
goals, plans, objectives and future events. MAKO intends such
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Reform Act of 1995. In some cases, forward-looking statements can
be identified by the following words: "may," "will," "could,"
"would," "should," "expect," "intend," "plan," "anticipate,"
"believe," "estimate," "predict," "project," "potential,"
"continue," "ongoing," or the negative of these terms or other
comparable terminology, although not all forward-looking statements
contain these words. These statements are based on the current
estimates and assumptions of our management as of the date of this
press release and are subject to risks, uncertainties, changes in
circumstances, assumptions and other factors that may cause actual
results to differ materially from those indicated by
forward-looking statements, many of which are beyond MAKO's ability
to control or predict. Such factors, among others, may have a
material adverse effect on MAKO's business, financial condition and
results of operations and may include the potentially significant
impact of a continued economic downturn or delayed economic
recovery on the ability of MAKO's customers to secure adequate
funding, including access to credit, for the purchase of MAKO's
products or cause MAKO's customers to delay a purchasing decision,
changes in general economic conditions and credit conditions,
changes in the availability of capital and financing sources for
our company and our customers, unanticipated changes in the timing
and duration of the sales cycle for MAKO's products or the vetting
process undertaken by prospective customers, changes in competitive
conditions and prices in MAKO's markets, changes in the
relationship between supply of and demand for our products,
fluctuations in costs and availability of raw materials, finished
goods, and labor, changes in other significant operating expenses,
slowdowns, delays, or inefficiencies in MAKO's product research and
development cycles, unanticipated issues relating to intended
product launches, decreases in sales of MAKO's principal product
lines, decreases in utilization of MAKO's principal product lines
or in procedure volume or system utilizations, increases in
expenditures related to increased or changing governmental
regulation or taxation of MAKO's business, both nationally and
internationally, unanticipated issues in complying with domestic or
foreign regulatory requirements related to MAKO's current products,
including initiating and communicating product actions or product
recalls and meeting Medical Device Reporting requirements and other
required reporting to the United States Food and Drug
Administration, or securing regulatory clearance or approvals for
new products or upgrades or changes to MAKO's current products,
developments adversely affecting our actual and potential sales
activities outside the United States, increases in cost containment
efforts by group purchasing organizations, the impact of the United
States healthcare reform legislation enacted in March 2010 on
hospital spending, reimbursement, unanticipated changes in
reimbursement to our customers for our products, and the taxing of
medical device companies, any unanticipated impact arising out of
the securities class action or any other litigation, inquiry, or
investigation brought against MAKO, loss of key management and
other personnel or inability to attract such management and other
personnel, increases in costs of retaining a direct sales force and
building a distributor network, unanticipated issues related to, or
unanticipated changes in or difficulties associated with, the
recruitment of agents and distributors of our products, and
unanticipated intellectual property expenditures required to
develop, market, and defend MAKO's products or market position.
These and other risks are described in greater detail under Item
1A, "Risk Factors," in MAKO's periodic filings with the Securities
and Exchange Commission, including MAKO's annual report on Form
10-K for the year ended December 31, 2012 filed on February 28,
2013. Given these uncertainties, undue reliance should not be
placed on these forward-looking statements. MAKO does not undertake
any obligation to release any revisions to these forward-looking
statements publicly to reflect events or circumstances after the
date of this press release or to reflect the occurrence of
unanticipated events.
"MAKOplasty®," "RESTORIS®," "RIO®," as well as the "MAKO" logo,
whether standing alone or in connection with the words "MAKO
Surgical Corp." are trademarks of MAKO Surgical Corp.
CONTACT: Investors:
MAKO Surgical Corp.
954-628-1706
investorrelations@makosurgical.com
or
Westwicke Partners
Mark Klausner
443-213-0500
makosurgical@westwicke.com
Mako Surgical Corp. (MM) (NASDAQ:MAKO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mako Surgical Corp. (MM) (NASDAQ:MAKO)
Historical Stock Chart
From Jul 2023 to Jul 2024